0R15 8884.0068 1.4156% 0R1E 9171.0 0.0% 0M69 None None% 0R2V 255.5 0.3929% 0QYR 1619.0 0.0% 0QYP 434.5 -0.344% 0RUK None None% 0RYA 1600.0 4.5752% 0RIH 195.2 1.3763% 0RIH 195.2 1.3763% 0R1O 225.5 9877.8761% 0R1O None None% 0QFP None None% 0M2Z 255.0 0.2457% 0VSO 33.3 -6.4738% 0R1I None None% 0QZI 596.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 236.3943 1.5483%
Last update at 2024-06-04T03:29:59.866282Z
Jounce dumps Redx Pharma for acquisition by Concentra; to cut 84% of jobs
Mon 27 Mar 23, 02:48 PMJounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciences
Thu 16 Mar 23, 03:32 PMWhy Jounce Therapeutics Shares Are Trading Higher Today
Thu 23 Feb 23, 03:39 PMUPDATE 1-Biotech firms Redx Pharma and Jounce Therapeutics to merge in $425 mln deal
Thu 23 Feb 23, 09:30 AMRedx and Jounce Announce Recommended Business Combination
Thu 23 Feb 23, 07:30 AM| Breakdown | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 |
| Income before tax | -17.80400M | -21.44300M | -9.16800M | -6.33500M | -10.14600M |
| Minority interest | - | - | - | - | - |
| Net income | -18.00500M | -21.57600M | -9.21300M | -4.31800M | -8.84500M |
| Selling general administrative | 10.23M | 6.46M | 0.05M | 0.05M | 0.22M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 18.69M | 10.04M | 5.68M | 2.78M | 0.13M |
| Reconciled depreciation | 0.89M | 0.63M | 0.67M | 0.09M | 0.16M |
| Ebit | -16.26600M | -19.74500M | -8.27400M | -7.19300M | -10.14500M |
| Ebitda | -15.19300M | -19.09900M | -7.60200M | -7.09000M | -9.98100M |
| Depreciation and amortization | 1.07M | 0.65M | 0.67M | 0.10M | 0.16M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -16.26600M | -19.74500M | -8.27400M | -7.19300M | -9.19900M |
| Other operating expenses | 37.25M | 29.78M | 13.96M | 10.32M | 9.33M |
| Interest expense | 1.73M | 1.71M | 0.97M | 0.10M | 0.00100M |
| Tax provision | 0.20M | 0.13M | 0.04M | -2.01700M | -1.30100M |
| Interest income | 0.19M | 0.01M | 0.00700M | 0.01M | 0.02M |
| Net interest income | -1.53800M | -1.69800M | -0.96700M | -0.09000M | 0.02M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 0.20M | 0.13M | 0.04M | -2.01700M | -1.30100M |
| Total revenue | 18.69M | 10.04M | 5.68M | 3.13M | 0.13M |
| Total operating expenses | 37.25M | 29.78M | 13.96M | 9.97M | 9.33M |
| Cost of revenue | - | - | 0.00000M | 0.35M | 9.24M |
| Total other income expense net | -1.53800M | -1.69800M | -0.89400M | 0.86M | -0.94700M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -18.00500M | -21.57600M | -9.21300M | -4.31800M | -8.84500M |
| Net income applicable to common shares | -18.00500M | -21.57600M | -9.21300M | -4.31800M | -8.84500M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Total assets | 25.64M | 62.48M | 39.55M | 33.59M | 6.36M |
| Intangible assets | - | 0.09M | 0.10M | 0.10M | 0.11M |
| Earning assets | - | - | - | - | - |
| Other current assets | - | 5.52M | 6.26M | 1.96M | 2.10M |
| Total liab | 22.28M | 29.16M | 26.41M | 30.90M | 4.87M |
| Total stockholder equity | 3.35M | 33.32M | 13.13M | 2.69M | 1.49M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 0.84M | 4.89M | 4.32M | 7.07M | 0.95M |
| Common stock | 3.35M | 3.35M | 2.75M | 1.95M | 1.26M |
| Capital stock | 3.35M | 3.35M | 2.75M | 1.95M | 1.26M |
| Retained earnings | -113.82700M | -81.31300M | -64.22600M | -42.21300M | -34.14200M |
| Other liab | - | - | - | - | - |
| Good will | - | 0.31M | 0.31M | 0.31M | 0.31M |
| Other assets | - | - | - | - | - |
| Cash | 18.09M | 53.85M | 29.55M | 27.51M | 3.70M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 21.01M | 27.20M | 9.59M | 10.93M | 4.87M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | -0.41100M | -35.54900M | -12.15600M | -7.04300M | -3.23600M |
| Short term debt | 16.41M | 16.35M | 0.57M | 0.50M | 0.47M |
| Short long term debt | 15.73M | 15.73M | - | 0.00000M | 0.47M |
| Short long term debt total | 17.68M | 18.30M | 17.40M | 20.47M | 0.47M |
| Other stockholder equity | 113.83M | 111.28M | 74.61M | 42.95M | 34.37M |
| Property plant equipment | - | 2.70M | 3.33M | 3.71M | 0.13M |
| Total current assets | 23.30M | 59.38M | 35.81M | 29.47M | 5.81M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 32.92M | 12.73M | 2.28M | 1.07M |
| Short term investments | - | - | - | - | - |
| Net receivables | 5.21M | 5.50M | 6.26M | 0.84M | 1.43M |
| Long term debt | - | 0.00000M | 14.25M | 16.76M | - |
| Inventory | - | - | - | - | - |
| Accounts payable | 3.76M | 5.96M | 4.70M | 3.36M | 3.44M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | -1.79400M | -1.14300M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 1.95M | 1.26M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | - | - | 0.41M | - | 0.55M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 2.33M | 3.10M | 3.73M | 4.12M | 0.55M |
| Capital lease obligations | 1.95M | 2.57M | 3.15M | 3.71M | - |
| Long term debt total | - | - | - | - | - |
| Breakdown | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 |
| Investments | -0.24100M | -0.75400M | -0.05500M | 0.03M | -0.10900M |
| Change to liabilities | -5.59300M | -1.41400M | 7.33M | -0.71100M | -8.96300M |
| Total cashflows from investing activities | -0.24100M | -0.75400M | -0.05500M | 0.03M | -0.10900M |
| Net borrowings | -0.81600M | -0.78600M | 22.89M | 1.00M | 1.00M |
| Total cash from financing activities | 32.98M | 24.14M | 23.47M | 1.87M | -0.04900M |
| Change to operating activities | - | - | - | - | - |
| Net income | -18.00500M | -21.57600M | -9.21300M | -4.31800M | -8.84500M |
| Change in cash | 24.30M | 2.04M | 23.81M | -2.76700M | -17.33500M |
| Begin period cash flow | 29.55M | 27.51M | 3.70M | 6.47M | 23.81M |
| End period cash flow | 53.85M | 29.55M | 27.51M | 3.70M | 6.47M |
| Total cash from operating activities | -8.47000M | -21.37900M | 0.40M | -4.66800M | -17.17700M |
| Issuance of capital stock | 34.57M | 25.98M | 2.10M | - | 0.00000M |
| Depreciation | 0.89M | 0.63M | 0.67M | 0.09M | 0.16M |
| Other cashflows from investing activities | - | - | 0.00400M | 0.06M | 0.02M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | - | - | - | - | - |
| Change to account receivables | 7.63M | -4.65100M | -0.90500M | 0.45M | 0.57M |
| Sale purchase of stock | - | 25.98M | 2.10M | - | - |
| Other cashflows from financing activities | -1.58600M | -1.83700M | 26.37M | 1.87M | -0.04900M |
| Change to netincome | 6.61M | 5.63M | 2.52M | -0.17600M | -0.10500M |
| Capital expenditures | 0.26M | 0.75M | 0.06M | 0.03M | 0.13M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 2.04M | -6.06500M | 6.42M | -0.26500M | -8.39100M |
| Stock based compensation | 4.37M | 3.79M | 0.57M | 0.04M | - |
| Other non cash items | 2.25M | 1.70M | 0.96M | -0.92500M | -0.38700M |
| Free cash flow | -8.73200M | -22.13300M | 0.34M | -4.69600M | -17.30900M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (GBP) | Price (GBP) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| REDX Redx Pharma Plc |
- -% | - | - | - | 21.29 | 25.51 | 20.27 | -2.8363 |
| ONT Oxford Nanopore Technologies Ltd |
- -% | 135.30 | - | - | 10.88 | 2.75 | 8.77 | -16.7946 |
| GNS Genus PLC |
- -% | 1524.00 | 42.59 | 25.71 | 2.08 | 2.46 | 2.31 | 16.39 |
| PRTC PureTech Health plc |
-1.6 1.02% | 154.80 | - | - | 35.55 | 1.04 | 95.87 | -4.5333 |
| AVCT Avacta Group PLC |
- -% | 49.50 | - | - | 23.19 | 14.78 | 20.75 | -10.4566 |
Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating anti-cancer and fibrosis targets in the areas of unmet medical needs. The company also develops RXC004, a porcupine inhibitor that is in Phase II clinical trial for targeted therapy of Wnt-ligand driven cancer; and RXC007, an oral selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor for the treatment of fibrotic diseases. In addition, it develops RXC008, a gastrointestinal targeted ROCK inhibitor to treat crohn's disease-associated fibrosis; discoidin domain receptors (DDRs) inhibitor for the treatment of multiple fibrotic conditions; and RXC006, a porcupine inhibitor targeting fibrotic diseases, including idiopathic pulmonary fibrosis. The company has a research collaboration agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates for two cancer targets in the RAS-RAF-MAP kinase pathway. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.
Alderley Park, Macclesfield, United Kingdom, SK10 4TG
| Name | Title | Year Born |
|---|---|---|
| Ms. Lisa Mary Whewell Anson | CEO & Exec. Director | 1970 |
| Dr. James Mead | Chief Operating Officer | 1978 |
| Mr. Peter J. Collum | Chief Financial Officer | NA |
| Dr. Richard Armer | Chief Scientific Officer | NA |
| Dr. Karl Hard Ph.D. | Head of Investor Relations | 1962 |
| Ms. Claire Solk | Gen. Counsel & Company Sec. | NA |
| Ms. Caitlin Pearson | Head of Communications | NA |
| Dr. Jane Robertson | Chief Medical Officer | NA |
| Dr. Cliff Jones | Sr. VP of Chemistry, DMPK & Intellectual Property | NA |
| Dr. Caroline Phillips | Sr. VP of Biology | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
UK 
AU
CA
US
NZ
Please wait processing your request...